T&L Reports Q1 2026 Consolidated Sales of KRW 45.07B, Operating Profit of KRW 18.27B, Net Profit of KRW 16.44B

Q1 2026 consolidated sales KRW 45.07B (down 12.2% YoY), operating profit KRW 18.27B, net profit KRW 16.44B, EPS KRW 2,051
Key products: Hydrocolloid (78.6% of sales), Polyurethane foam (7.1%), Microneedles (3.4%)
Overseas sales ~76%, major customers: C Co. (68.5%), N Co. (6.3%)
Financial position: Total assets KRW 239.6B, liabilities KRW 33.9B, equity KRW 205.8B (adjusted debt ratio negative, net cash)
Cash and cash equivalents KRW 40.26B, no debt
Treasury shares 110,869 shares (1.36%) held for stock price stabilization; dividend payable of KRW 12.03B set
R&D expenses KRW 0.99B (2.2% of sales), government projects
Subsidiaries: China Jiaxing Tailong (net profit KRW 0.13B), T&L Healthcare and T&L Europe in loss but immaterial
No pending lawsuits, no contingencies